Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

2 articles from the last 30 days matching "glioblastoma"

Clinical trialUNITERAREApr 4

New Recruiting Trial: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)

Researchers are testing a new drug called JL15003 to see if it can safely treat glioblastoma, a serious brain cancer that has come back after previous treatment. This is an early-stage study that will check both how safe the drug is and whether it helps patients live longer or feel better. The study is now accepting patients and will run starting in April 2026.

WHY IT MATTERSThis trial offers a potential new treatment option for patients with recurrent glioblastoma, a condition with very limited treatment choices after initial therapy fails.
👁 Watch this spaceglioblastomarecurrent glioblastomaRead →
Clinical trialUNITERAREApr 3

New Recruiting Trial: Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Researchers are looking for patients with a specific type of brain cancer called glioblastoma (GBM) to test a new drug combination. The study will test a drug called silevertinib combined with temozolomide in patients whose tumors have certain genetic features (unmethylated MGMT and EGFRvIII). This is an early-stage study to see if this combination works better than current treatments.

WHY IT MATTERSThis trial targets newly diagnosed GBM patients with unmethylated MGMT and EGFRvIII mutations—a subgroup with historically poor prognosis—and offers access to a potentially more effective treatment combination before it becomes widely available.
→ You can act on thisglioblastomaglioblastoma multiformeRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases